Incyte Corp. PT Raised to $75.00 at Barclays (INCY)
Research analysts at Barclays lifted their target price on shares of Incyte Corp. (NASDAQ:INCY) from $64.00 to $75.00 in a report released on Thursday, AnalystRatings.Net reports. The firm currently has an “overweight” rating on the stock. Barclays’ price target would indicate a potential upside of 7.93% from the company’s current price.
Shares of Incyte Corp. (NASDAQ:INCY) traded down 3.91% on Thursday, hitting $66.14. The stock had a trading volume of 2,731,448 shares. Incyte Corp. has a 1-year low of $18.23 and a 1-year high of $69.98. The stock has a 50-day moving average of $60.36 and a 200-day moving average of $43.65. The company’s market cap is $10.656 billion.
Incyte Corp. (NASDAQ:INCY) last announced its earnings results on Wednesday, February 12th. The company reported ($0.15) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.10) by $0.05. The company had revenue of $97.10 million for the quarter, compared to the consensus estimate of $98.04 million. During the same quarter in the prior year, the company posted $0.14 earnings per share. The company’s quarterly revenue was down 14.7% on a year-over-year basis. On average, analysts predict that Incyte Corp. will post $-0.05 earnings per share for the current fiscal year.
A number of other firms have also recently commented on INCY. Analysts at UBS AG raised their price target on shares of Incyte Corp. from $74.00 to $90.00 in a research note on Thursday. They now have a “buy” rating on the stock. Separately, analysts at Canaccord Genuity raised their price target on shares of Incyte Corp. from $79.00 to $85.00 in a research note on Thursday. They now have a “buy” rating on the stock. Finally, analysts at Nomura raised their price target on shares of Incyte Corp. to $83.00 in a research note on Tuesday, January 21st. One investment analyst has rated the stock with a sell rating, one has given a hold rating and thirteen have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $59.40.
Incyte Corporation (NASDAQ:INCY) is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat serious unmet medical needs.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.